Preferred Pharmaceuticals Recalls Ranitidine Tablets Due to NDMA Impurity
Preferred Pharmaceuticals is recalling 150 mg Ranitidine tablets because of detected NDMA impurity. The affected products were distributed to physicians in seven states.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. According to the rubric, FDA Class II recalls involving significant health risks like NDMA impurities are categorized as Severe (Score 4), particularly when hospitalization reports or significant injury risks are associated with the hazard class, though the source text does not explicitly report hospitalizations, the Class II designation for a drug impurity aligns with the Severe criteria for significant risk.
Plain-English summary
Preferred Pharmaceuticals, Inc. is recalling 150 mg Ranitidine tablets due to the presence of the NDMA impurity. The recall includes 30, 60, 90, and 100-count bottles with specific NDC codes. The total quantity involved is 221,710 tablets.
The recall was initiated because of Current Good Manufacturing Practice (CGMP) deviations, specifically the detection of the NDMA impurity in the product. The source text does not specify which lots are affected other than stating 'All lots within expiry.'
The affected products were distributed to physicians in Alabama, Arizona, California, Florida, Georgia, Indiana, and South Carolina. Consumers and healthcare providers should stop using the recalled products and contact their pharmacist or physician for guidance on alternatives.
The recalled product
- Product
- Preferred Pharmaceuticals, Inc, Ranitidine Tablets, 150 mg, a) 30 count bottles (NDC: 68788-7388-3), b) 60 count bottles (NDC: 68788-7388-6), c) 90 count bottles (NDC: 68788-7388-9), d) 100 count bottles (NDC: 68788-7388-1)
- Manufacturer
- Preferred Pharmaceuticals, Inc
- Category
- Drug — Prescription Medication
- Affected units
- 221,710
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot #: All lots within expiry
Distribution
Part of a larger recall action
This product is one of 2 recalled by Preferred Pharmaceuticals, Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Preferred Pharmaceuticals, Inc
See all →- HighGeri-Care artificial tears lubricant eye drops recalled over sterility assurance
FDA (Drugs) · 2026-04-15
- ModerateOndansetron blister packs recalled because tablets are falling out
FDA (Drugs) · 2025-12-24
- ModerateClindamycin Hydrochloride Capsules Recalled for cGMP Deviations
FDA (Drugs) · 2025-05-07
- HighIbuprofen Tablets Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2024-09-04
- HighDuloxetine Delayed-Release Capsules Recalled for Nitrosamine Impurity
FDA (Drugs) · 2024-05-29
Same hazard · ndma impurity
See all →- SeverePreferred Pharmaceuticals Recalls Metformin HCl Extended Release Tablets
FDA (Drugs) · 2021-05-26
- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2021-02-10
- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2021-01-20
- SevereDenton Pharma Recalls Metformin Hydrochloride Tablets Due to NDMA Impurity
FDA (Drugs) · 2020-11-11
- SevereDirect Rx Recalls Metformin Hydrochloride Extended Release Due to NDMA Impurity
FDA (Drugs) · 2020-11-11